Life sciences company Thermo Fisher (NYSE:TMO) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 6.2% year on year to $11...
What Happened? Shares of life sciences company Thermo Fisher (NYSE:TMO) fell 10.5% in the afternoon session after the company reported first-quarter results ...
Life sciences company Thermo Fisher (NYSE:TMO) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 6.2% year on year to $11.01 billion. Its n...
Life sciences company Thermo Fisher (NYSE:TMO) will be reporting earnings this Thursday before the bell. Here’s what to look for. Thermo Fisher beat analysts...
The Iran conflict has given investors a reason to sell just about everything. The Dow is in correction territory. Oil prices have surged. Entire sectors are trading as if a recession is already here. But inside those beaten-down groups, a handful of stocks are quietly doing something different.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a...
In a move that has sent shockwaves through both the pharmaceutical and technology sectors, Eli Lilly and Company (NYSE: LLY) announced today, April 6, 2026, the finalized acquisition of Contessa, a pioneer in AI-driven clinical research, for a staggering $47.8 billion. The deal represents the largest "Tech-Bio" merger in
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
INDIANAPOLIS — In a move that has sent shockwaves through the global financial markets, Eli Lilly and Company (NYSE: LLY) announced early this morning, April 1, 2026, a definitive agreement to acquire Contessa, a powerhouse in clinical research and next-generation pharmaceutical development. The massive $47.8 billion all-cash transaction represents the
As the first quarter of 2026 draws to a close, the healthcare and life sciences sectors are grappling with a "new normal" defined by capital conservatism and geopolitical friction. Industry bellwethers, once buoyed by post-pandemic expansion and aggressive R&D spending, are now issuing sober forecast revisions that reflect a
WALTHAM, MA — In a market defined by shifting geopolitical alliances and a renewed "flight to quality," Thermo Fisher Scientific (NYSE:TMO) has once again asserted its dominance as the bedrock of the life sciences sector. Reporting its fourth-quarter 2025 results on January 29, 2026, the company delivered a robust earnings
